SYREHealthcareMid-Cap
Spyre Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Spyre Therapeutics, Inc. (SYRE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are SYRE insiders buying or selling?
Spyre Therapeutics, Inc. insiders reported 12 open-market buys ($2.8M) and 29 sells ($428.1M) across 41 Form 4 filings — a net selling position of $425.4M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 3, 2026)
Total Form 4 filings
41
SEC EDGAR
Insider filers
13
Insider buys (12)
$2.8M
Insider sells (29)
$428.1M
Insider sentiment
Net sellingNet insider flow of $425.4M in net selling.
Recent SYRE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 3, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $87.74 | $658.0K |
| Jul 3, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.3K | $87.70 | $730.9K |
| Jul 3, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $87.69 | $1.3M |
| Jun 27, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 15.0K | $87.13 | $1.3M |
| Jun 24, 2026 | Tomas Kiselak | Director | Sale | 4.7M | $85.31 | $399.7M |
| Jun 24, 2026 | Michael Thomas Henderson | Director | Sale | 20.0K | $100.00 | $2.0M |
| Jun 4, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.3K | $75.00 | $625.0K |
| Jun 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $70.43 | $1.1M |
| Jun 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $71.06 | $532.9K |
| May 9, 2026 | Michael Thomas Henderson | Director | Sale | 80.0K | $74.40 | $6.0M |
| May 2, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 12.5K | $71.37 | $892.1K |
| May 2, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 78.3K | $71.50 | $5.6M |
| May 2, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $71.37 | $1.1M |
| Apr 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $49.33 | $739.9K |
| Apr 4, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.0K | $50.00 | $397.9K |
| Apr 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $49.34 | $370.1K |
| Mar 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 2.5K | $40.65 | $101.6K |
| Mar 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $42.19 | $632.9K |
| Feb 5, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $32.80 | $492.0K |
| Jan 7, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $30.68 | $460.1K |
| Nov 6, 2025 | Cameron Turtle | Chief Executive Officer | Sale | 45.0K | $23.33 | $1.0M |
| Sep 3, 2025 | Scott L Burrows | Chief Financial Officer | Sale | 18.4K | $16.26 | $299.6K |
| Nov 8, 2024 | Jeffrey W. Albers | Director | Sale | 6.7K | $36.76 | $246.3K |
| Oct 28, 2024 | Jeffrey W. Albers | Director | Sale | 300 | $36.43 | $10.9K |
| Sep 5, 2024 | Scott L Burrows | Chief Financial Officer | Sale | 18.5K | $28.17 | $522.1K |
Showing the 25 most recent of 41 Form 4 filings for Spyre Therapeutics, Inc..
Most active SYRE insiders
- Cameron Turtle8 filings
- Scott L Burrows8 filings
- Anthony G. Quinn7 filings
- Sheldon Sloan4 filings
- Novartis Bioventures Ltd3 filings
Ask anything about SYRE insider activity
Use Trabud's AI agent to query Spyre Therapeutics, Inc.'s Form 4 history in plain English — "Show me SYRE CEO purchases this year" or compare it against any other ticker.
Open the AI agentSYRE insider trading FAQ
Are Spyre Therapeutics, Inc. insiders buying or selling?
Across 41 SEC Form 4 filings, Spyre Therapeutics, Inc. (SYRE) insiders reported 12 open-market purchases totaling $2.8M and 29 sales totaling $428.1M. That is a net selling position of $425.4M.
How many insiders trade SYRE stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Spyre Therapeutics, Inc.. The most recent filing was accepted on Jul 3, 2026.
Where does Trabud get SYRE insider trading data?
All SYRE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.